Clinical Trial Update: Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating Tarlatamab plus Durvalumab versus Durvalumab alone as first-line therapy for extensive-stage small-cell lung cancer, with the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tarlatamab

Snippet

Sponsor: Amgen | Conditions: Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING